Prevention of atherothrombosis in adults:
in patients who have had myocardial infarction (the start of treatment is a few days, but no later than 35 days after the onset), ischemic stroke (the start of treatment is 7 days, but no later than 6 months after the onset) or who have been diagnosed with the disease peripheral arteries (damage to arteries and atherothrombosis of vessels of the lower extremities);
in patients with acute coronary syndrome:
̶ with acute coronary syndrome without ST segment elevation (unstable angina or myocardial infarction without Q wave), including in patients who had a stent installed during percutaneous coronary angioplasty, in combination with acetylsalicylic acid (aSA);
with acute myocardial infarction, with an increase in the ST segment in combination with acetylsalicylic acid (in patients who receive standard medication and who are shown thrombolytic therapy).
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation. Assign clopidogrel in combination with ASA to adult patients with atrial fibrillation, who have at least one risk factor for the occurrence of vascular events, who have contraindications for treatment with vitamin K antagonists (aVK) and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events including stroke. See also the section “Pharmacological properties”.